Menu
Recruiting NCT07739277

Transverse vs. Longitudinal Serratus Anterior Plane Block in Breast Surgery

No phase Interventional Fascial Plane Block Pain, Postoperative Breast Surgery Acute Pain

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Transverse SAP Block, Longitudinal SAP Block.
Who it may be relevant to
Registry conditions: Fascial Plane Block, Pain, Postoperative, Breast Surgery, Acute Pain. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Efficacy of Transverse Versus Longitudinal Ultrasound Probe Orientation for Serratus Anterior Plane Block on Postoperative Pain in Breast Surgery: A Prospective Randomized Controlled Trial

Overview

The aim of this prospective, randomized controlled trial is to compare the analgesic efficacy of transverse versus longitudinal ultrasound probe orientations during Serratus Anterior Plane (SAP) block in patients undergoing breast surgery. The study hypothesizes that the longitudinal approach (probe parallel to the ribs) may provide better craniocaudal spread of the local anesthetic, thereby resulting in lower postoperative Visual Analog Scale (VAS) scores and reduced opioid consumption compared to the standard transverse approach.

Interventions

  • Procedure Transverse SAP Block
    Transverse serratus anterior plane block will be performed on the patients using 20 mL of 0.375% bupivacaine under ultrasound guidance.
  • Procedure Longitudinal SAP Block
    Longitudinal serratus anterior plane block will be performed on the patients using 20 mL of 0.375% bupivacaine under ultrasound guidance.

Primary outcome measures

  • Postoperative Pain Intensity [Time frame: 4 hour after surgery]
Secondary outcome measures (5)
  • Postoperative Pain Intensity [Time frame: Up to 24 hours]
  • Postoperative Pain Intensity [Time frame: Up to 24 hours]
  • Total Postoperative Opioid Consumption [Time frame: Up to 24 hours]
  • Area Under Curve for Pain [Time frame: Up to 24 hours]
  • Assessment of Sensory Blockade Extent [Time frame: Evaluated at 20 minutes following block administration.]

Eligibility criteria

Inclusion criteria

  • Patients aged between 18 and 65 years
  • American Society of Anesthesiologists (ASA) physical status I, II, or III
  • BMI between 18 - 30 kg/m2
  • Patients scheduled for elective breast surgery
  • Ability to provide written informed consent

Exclusion criteria

  • Known allergy to local anesthetics
  • Infection at the injection site
  • Severe coagulopathy or use of anticoagulants
  • Chronic opioid use or history of neuropathic pain

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

Turkey (Türkiye) · 1 center
  • Ankara Etlik City Hospital — Ankara

Identifiers

NCT: NCT07739277 · AEŞH-EK-2026-152

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗